ClinicalTrials.gg
RecruitingNCT07648823Updated Jun 16, 2026

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

An Early Phase 1 interventional study of [177Lu]Lu-XT771 in Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma and Glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Beijing Tiantan Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Glioblastoma by Beijing Tiantan Hospital — 4 open to participants now, 5 under way, 1 of them phase 3. Glioblastoma · Beijing Tiantan Hospital.

Planned enrollment
10th of 10
5 · median 27
Started
2026
with 2 others
Phase 1
7 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Glioblastoma by Beijing Tiantan Hospital, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 1, and was the 9th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

4 of the 11 studies in Glioblastoma by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glioblastoma by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer. [177Lu]Lu-XT771 is designed to specifically target and deliver beta radiation directly to tumor cells that overexpress carbonic anhydrase IX and XII (CA IX and CA XII).

This early-phase, investigator-initiated trial will enroll a small group of approximately 3-5 patients, each receiving a single dose of [177Lu]Lu-XT771. The drug will be administered locoregionally via an implanted Ommaya reservoir, directly into the tumor cavity. Following administration, patients will be closely monitored using single-photon emission computed tomography/computed tomography (SPECT/CT) to assess the biodistribution of the drug and to quantify the absorbed radiation dose to both the tumor and normal organs.

The study will also document all adverse events to characterize the safety profile of the treatment and will provide a preliminary assessment of its anti-tumor activity, as measured by progression-free survival. The information gathered from this exploratory study will be used to determine the recommended safe starting dose for future Phase I clinical trials.

Read the detailed description

Background and Rationale:

Glioblastoma (GBM) is a highly aggressive brain tumor associated with poor prognosis, particularly upon recurrence. Standard therapeutic options for recurrent GBM are limited, representing an urgent unmet medical need. Carbonic anhydrase IX (CA IX) and XII (CA XII) are transmembrane proteins specifically overexpressed in the hypoxic microenvironment of glioblastoma. They play critical roles in tumor progression and treatment resistance, yet they exhibit scarce expression in normal tissues. This differential expression makes them ideal targets for targeted radioligand therapy.

Investigational Drug: [177Lu]Lu-XT771 is an investigational, first-in-human (FIH) targeted radiopharmaceutical. It is designed to specifically bind to CA IX and CA XII receptors on the tumor cell surface. Upon binding, the Lutetium-177 isotope delivers localized beta radiation directly to the tumor cells, aiming to destroy the tumor while minimizing radiation exposure to surrounding healthy brain tissue. Preclinical in vivo models have demonstrated that local administration of [177Lu]Lu-XT771 results in prolonged tumor retention, high cumulative radiation absorbed doses, and significant inhibition of tumor proliferation.

Study Procedures: In this exploratory, early-phase dosimetric study, eligible patients with recurrence of glioblastoma will undergo surgical placement of an Ommaya reservoir. Prior to the therapeutic injection, a leakage test using a [68Ga]Ga-XT771 tracer will be performed to ensure there is no leakage into the subcutaneous or subarachnoid spaces. Once safety is confirmed, a single locoregional dose of 3-5 mCi of [177Lu]Lu-XT771 will be directly injected into the tumor cavity via the Ommaya reservoir. Patients will be isolated post-injection until their systemic radioactivity levels fall below the required safety discharge standards.

Monitoring and Dosimetry Assessments: To precisely evaluate the radiation dosimetry and biodistribution, patients will undergo a series of whole-body planar scintigraphy and head/abdomen SPECT/CT scans at multiple pre-defined time points post-injection (e.g., 30 minutes, 2 hours, 24 hours, 48 hours, 72 hours, and 5-7 days). These scans will quantify the drug's distribution and the radiation dose absorbed by both the tumor lesions and normal organs (such as the kidneys).

Patients will be continuously monitored for safety and adverse events. Efficacy will be assessed preliminarily using contrast-enhanced head MRI based on RANO 2.0 criteria. The dosimetry, safety, and pharmacokinetic data gathered from this trial will be crucial for calculating and determining the recommended safe starting dose for a subsequent, larger-scale Phase I clinical trial.

03

Conditions studied

  • Recurrent Glioblastoma (WHO-Grade IV Glioma)
  • Recurrent Glioblastoma
  • Glioblastoma (GBM)
  • Recurrent Glioblastoma IDH Wildtype

Browse trials for

Keywords

  • Recurrent Glioblastoma
  • [177Lu]Lu-XT771
  • Carbonic Anhydrase IX
  • Carbonic Anhydrase XII
  • Safety and Tolerability
  • Dosimetry
  • Efficacy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has fully understood the study and voluntarily signed the form.
  2. Age ≥ 18 and ≤ 80 years old.
  3. (ECOG) performance status score of 0 to 1.
  4. of at least 3 months.
  5. confirmed glioblastoma (based on the 2021 WHO Classification of Tumors of the Central Nervous System, 5th edition), and confirmed CA IX/CA XII positive by histology or [68Ga]Ga-XT771 PET/CT.
  6. Histologically confirmed recurrence of glioblastoma following prior treatments.
  7. Suitable for Ommaya reservoir placement and meets the conditions for drug administration, as judged by the investigator.
  8. Tumor resection cavity volume between 2.5 and 25 cm\^3.
  9. On a stable or decreasing dose of (≤5 mg/day of dexamethasone or equivalent) for at least 1 week prior to the first dose.
  10. Toxicity from prior anti-tumor treatments (e.g., chemotherapy, radiotherapy, immunotherapy) recovered to ≤ Grade 1 (excluding alopecia).
  11. Adequate organ and bone marrow function meeting the following criteria:

    • Bone marrow: (ANC) ≥ 1.5 ×10\^9/L and white blood cell (WBC) count ≥ 3 ×10\^9 /L (without growth factor support within 28 days prior to dosing); count ≥ 75 ×10\^9/L; ≥ 90 g/L.
    • Hepatic function: Total ≤ 1.5 × (≤ 2.0 × ULN for subjects with liver ; ≤ 3.0 × ULN for subjects with confirmed Gilbert's syndrome); and AST ≤ 3 × ULN (\< 5 × ULN for subjects with liver metastases); Albumin > 30 g/L.
    • Renal function: Serum creatinine ≤ 1.5 × ULN and rate ≥ 50 mL/min.
    • Coagulation: ≤ 2.0, APTT ≤ 1.5 × ULN. (Exception: subjects receiving warfarin may have an INR between 2 and 3 inclusive).
  12. Fertile subjects (and their partners) must agree to use highly effective methods (e.g., condoms, oral or injectable contraceptives) during the treatment period and for 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Received anti-tumor treatments (including radiotherapy, chemotherapy, biological therapy, endocrine therapy, targeted therapy, etc.) within 4 weeks prior to dosing. Exceptions: (1) immunotherapy, nitrosoureas, or mitomycin C within 6 weeks prior to dosing; (2) oral fluorouracils and small molecule targeted drugs within 2 weeks or 5 half-lives (whichever is longer) prior to dosing; (3) Traditional Chinese Medicine with anti-tumor indication within 2 weeks prior to dosing; (4) cranial radiotherapy within 3 months prior to dosing.
  2. Received any other unapproved drug within 4 weeks prior to dosing.
  3. Underwent major organ surgery (excluding needle ) or experienced significant trauma within 4 weeks prior to dosing, or expected to require elective surgery during the study period.
  4. Known or suspected allergy to the study drug or its analogue components.
  5. Inability to undergo contrast-enhanced MRI scans (e.g., due to pacemakers, contrast agent allergy).
  6. Presence of active or uncontrolled infections requiring systemic intravenous treatment, or unexplained fever >38.5°C during the screening period or before dosing.
  7. Presence of severe coagulation disorders or evidence of significant bleeding risk; history of gastrointestinal bleeding; any Grade ≥2 bleeding event ( v5.0) within the past 6 months.
  8. Active (HBsAg positive and HBV-DNA > 500 IU/mL or above the lower limit of detection of the study center) or Active (HCV antibody positive and HCV-RNA > the lower limit of detection of the study center).
  9. Uncontrolled hypertension as judged by the investigator (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg despite standard treatment).
  10. History of severe cardiovascular disease, such as ventricular arrhythmias requiring clinical intervention; > 480 ms; acute coronary syndrome, congestive heart failure, stroke, or other ≥ Grade III cardiovascular events within 6 months prior to dosing; class II-IV or \< 50%.
  11. History of other uncured within the past 3 years or concurrently, except for curable in situ cancers (e.g., carcinoma in situ of the cervix, basal cell carcinoma of the skin).
  12. Presence of two or more intracranial lesions, extracranial , or tumors located in the infratentorial compartment or basal ganglia.
  13. Brain MRI indicating that the enhancing edge of the tumor invades the ventricular wall, or the surgical cavity communicates with the ventricle.
  14. Psychiatric disorders or poor compliance.
  15. Pregnant or lactating women.
  16. The investigator considers the subject unsuitable for participation in this clinical study due to other severe systemic diseases or other reasons.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    [177Lu]Lu-XT771

    All eligible participants with recurrence of glioblastoma will be assigned to this single experimental arm. Participants will receive a single-dose locoregional injection of 3-5 mCi of the investigational radiopharmaceutical, \[177Lu\]Lu-XT771. The drug will be administered directly into the tumor resection cavity via a surgically implanted Ommaya reservoir. Prior to the therapeutic injection, a leakage test using a \[68Ga\]Ga-XT771 tracer (4-6 mCi) will be performed to ensure proper reservoir function and safety. Additionally, to prevent cerebral edema, participants will receive a prophylactic course of oral dexamethasone (4 mg, 3 times daily), starting 24 hours prior to the \[177Lu\]Lu-XT771 injection and continuing for a total of 4 days. Following the administration, participants will be isolated until radioactivity levels reach safe discharge standards and will undergo serial SPECT/CT imaging for radiation dosimetry assessments.

    Drug: [177Lu]Lu-XT771

Interventions

  • DrugLutetium-177Studies of Lutetium-177Lutetium-177 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    \[177Lu\]Lu-XT771 is a novel, first-in-human radiopharmaceutical designed to specifically target Carbonic Anhydrase IX (CA IX) and XII (CA XII), which are overexpressed in the glioblastoma microenvironment. Unlike systemic intravenous therapies, this intervention utilizes a highly localized delivery method: a single dose of 3-5 mCi \[177Lu\]Lu-XT771 is injected directly into the tumor resection cavity via a surgically implanted Ommaya reservoir. To ensure precise safety, two specific steps are required: 1) A mandatory pre-treatment leakage test using a \[68Ga\]Ga-XT771 tracer (4-6 mCi) with PET/CT imaging to rule out any leakage into the subcutaneous or subarachnoid spaces; and 2) The extraction of an equivalent volume of cerebrospinal fluid immediately prior to the therapeutic injection. Furthermore, to mitigate radiation-induced cerebral edema, the intervention is paired with a prophylactic regimen of oral dexamethasone (4 mg, three times daily) for 4 days.

06

What researchers measure

Primary outcomes

  1. Radiation Dosimetry

    To evaluate the radiation dosimetry and biodistribution of a single locoregional injection of \[177Lu\]Lu-XT771. It will be quantified using serial whole-body planar scintigraphy and SPECT/CT imaging to measure drug distribution and calculate the cumulative radiation absorbed dose in the tumor cavity and critical normal organs (e.g., kidneys). These dosimetric data will be used to determine the recommended starting dose for future Phase I trials.

    Time frame: 30 minutes, 2 hours, 24 hours, 48 hours, 72 hours, and 5-7 days post-injection

  2. Incidence and severity of adverse events and incidence of serious adverse events

    Safety and tolerability will be evaluated by monitoring the incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs). All AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Assessments include patient complaints, vital signs, physical examinations, 12-lead ECGs, and clinical laboratory abnormalities.

    Time frame: From the time of informed consent up to 30 days after the last dose

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from the date of \[177Lu\]Lu-XT771 administration until the first date of objectively documented radiographic disease progression or death from any cause. Tumor response and progression will be assessed using contrast-enhanced head MRI based on the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria.

    Time frame: Every 8 weeks from the date of injection until disease progression or completion of 1 year of follow-up, whichever occurs first.

07

Study locations

2 of 2 sites recruiting
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100070, China
    Recruiting
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Zhaohui Zhu, M.D. · Contact13611093752@163.com · +86 15909835868
    • Zhaohui Zhu, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the early-stage exploratory nature of this early Phase I trial, the small sample size, and confidentiality concerns.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 12 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 15, 2026
StartEst.
Jun 20, 2026
Primary completionEst.
Jun 20, 2027
CompletionEst.
Jun 1, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07648823
Responsible party
Deling Li (Vice President, Beijing Tiantan Hospital) — Principal investigator
First posted
Jun 15, 2026
Start date
Jun 20, 2026 (estimated)
Primary completion
Jun 20, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Li'ao Wang, M.D.
Contact
wangliao17@163.com
+86 15001171671
Deling Li, M.D.
Contact
lideling@bjtth.org
Deling Li, M.D.
principal investigator · Beijing Tiantan Hospital
Zhaohui Zhu, M.D.
principal investigator · Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion